Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnold Bolomsky

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Blood Advances|September 3, 2021
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myelomaArnold Bolomsky, Juho J Miettinen, Alina Malyutina, et al.
Cancer Cell|June 21, 2024
IRF4 requires ARID1A to establish plasma cell identity in multiple myelomaArnold Bolomsky, Michele Ceribelli, Sebastian Scheich, et al.
Cancer Research|June 23, 2021
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple MyelomaLenka Besse, Andrej Besse, Sara C Stolze, et al.
Cancer Discovery|May 4, 2023
Targeting N-linked Glycosylation for the Therapy of Aggressive LymphomasSebastian Scheich, Jiji Chen, Jiamin Liu, et al.
Nature Communications|September 17, 2022
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaYandan Yang, Arnold Bolomsky, Thomas Oellerich, et al.
Cancer Cell|January 12, 2024
Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagyJames D Phelan, Sebastian Scheich, Jaewoo Choi, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Blood Advances|September 3, 2021
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myelomaArnold Bolomsky, Juho J Miettinen, Alina Malyutina, et al.
Cancer Cell|June 21, 2024
IRF4 requires ARID1A to establish plasma cell identity in multiple myelomaArnold Bolomsky, Michele Ceribelli, Sebastian Scheich, et al.
Cancer Research|June 23, 2021
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple MyelomaLenka Besse, Andrej Besse, Sara C Stolze, et al.
Cancer Discovery|May 4, 2023
Targeting N-linked Glycosylation for the Therapy of Aggressive LymphomasSebastian Scheich, Jiji Chen, Jiamin Liu, et al.
Nature Communications|September 17, 2022
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myelomaYandan Yang, Arnold Bolomsky, Thomas Oellerich, et al.
Cancer Cell|January 12, 2024
Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagyJames D Phelan, Sebastian Scheich, Jaewoo Choi, et al.
Pageof 3